鼻内氯胺酮与鼻内芬太尼用于儿童疑似四肢骨折镇痛的随机对照可行性试验
该随机对照可行性试验纳入4–17岁因疑似孤立性四肢骨折导致急性疼痛、就诊于城市II级儿科创伤中心的儿童,比较鼻内亚麻醉剂量氯胺酮1 mg/kg与鼻内芬太尼1.5 μg/kg的耐受性和镇痛效果。主要结局为给药后60分钟内累积副作用和不良事件的发生频率,氯胺酮组副作用累积次数是芬太尼组的2.2倍,但无严重不良事件,两组均无患者需要干预。20分钟时氯胺酮组疼痛评分平均降低44±36,芬太尼组降低35±29(平均差9,95%CI -4至23)。作者认为数据支持开展更大规模的非劣效性试验,以更严格评估鼻内氯胺酮镇痛的安全性、有效性及潜在阿片类药物节约效益。
要点
- 在4–17岁疑似孤立性四肢骨折患儿中,鼻内氯胺酮1 mg/kg组60分钟内副作用累积次数是鼻内芬太尼1.5 μg/kg组的2.2倍,但无严重不良事件,两组均无患者需要干预。
- 氯胺酮组最常见副作用为口苦(37例,90.2%)、头晕(30例,73.2%)、嗜睡(19例,46.3%);芬太尼组为嗜睡(15例,36.6%)、口苦(9例,22%)、鼻痒(9例,22%)。
- 20分钟时疼痛评分平均降低氯胺酮组44±36 vs 芬太尼组35±29,平均差9(95%CI -4至23),原文结论为两组疼痛缓解相似。
- 两组均无患者出现呼吸系统副作用。
- 完成研究前接受氯胺酮程序性镇静者氯胺酮组28例(65%)、芬太尼组25例(57%)。
适用人群与场景
- 4至17岁因疑似孤立性四肢骨折导致急性疼痛、就诊于城市II级儿科创伤中心的儿童。
- 筛查629例,87例接受研究药物,82例有主要结局完整数据(每组41例)。
- 中位年龄8岁(四分位距6–11岁),62%为男性。
处置流程与药物剂量
- 鼻内氯胺酮1 mg/kg单次给药用于4–17岁疑似孤立性四肢骨折急性疼痛患儿。
- 鼻内芬太尼1.5 μg/kg单次给药用于同人群作为对照。
- 所有患者监测至末次研究药物给药后6小时或至收入病房或手术室。
红旗征与不能漏的情况
- 氯胺酮组副作用累积次数是芬太尼组的2.2倍,最常见为口苦(37例,90.2%)、头晕(30例,73.2%)、嗜睡(19例,46.3%),但无严重不良事件且无患者需要干预。
- 两组均无患者出现呼吸系统副作用。
研究设计与关键结果
- 研究类型:随机对照可行性试验;样本量:87例接受研究药物,82例主要结局可评估(每组41例);人群:4–17岁疑似孤立性四肢骨折急性疼痛患儿;干预:鼻内氯胺酮1 mg/kg vs 鼻内芬太尼1.5 μg/kg;主要终点:给药后60分钟内累积副作用和不良事件频率,氯胺酮组是芬太尼组的2.2倍,无严重不良事件,两组均无患者需要干预。
- 基线疼痛评分:氯胺酮组73±26 vs 芬太尼组69±26,平均差4(95%CI -7至15)。
- 20分钟疼痛评分平均降低:氯胺酮组44±36 vs 芬太尼组35±29,平均差9(95%CI -4至23)。
- 氯胺酮组最常见副作用:口苦37例(90.2%)、头晕30例(73.2%)、嗜睡19例(46.3%);芬太尼组最常见副作用:嗜睡15例(36.6%)、口苦9例(22%)、鼻痒9例(22%)。
- 完成研究前接受氯胺酮程序性镇静:氯胺酮组28例(65%)vs 芬太尼组25例(57%)。
证据类型、等级与局限
- 证据类型:随机对照可行性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为数据支持开展更大规模的非劣效性试验,以更严格评估鼻内氯胺酮镇痛的安全性、有效性及潜在阿片类药物节约效益。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We compared the tolerability and efficacy of intranasal subdissociative ketamine to intranasal fentanyl for analgesia of children with acute traumatic pain and investigated the feasibility of a larger noninferiority trial that could investigate the potential opioid-sparing effects of intranasal ketamine.
METHODS: This randomized controlled trial compared 1 mg/kg intranasal ketamine to 1.5 μg/kg intranasal fentanyl in children 4 to 17 years old with acute pain from suspected isolated extremity fractures presenting to an urban Level II pediatric trauma center from December 2015 to November 2016. Patients, parents, treating physicians, and outcome assessors were blinded to group allocation. The primary outcome, a tolerability measure, was the frequency of cumulative side effects and adverse events within 60 minutes of drug administration. The secondary outcomes included the difference in mean pain score reduction at 20 minutes, the proportion of patients achieving a clinically significant reduction in pain in 20 minutes, total dose of opioid pain medication in morphine equivalents/kg/hour (excluding study drug) required during the emergency department (ED) stay, and the feasibility of enrolling children presenting to the ED in acute pain into a randomized trial conducted under U.S. regulations. All patients were monitored until 6 hours after their last dose of study drug or until admission to the hospital ward or operating room.
RESULTS: Of 629 patients screened, 87 received the study drug and 82 had complete data for the primary outcome (41 patients in each group). The median (interquartile range) age was 8 (6-11) years and 62% were male. Baseline pain scores were similar among patients randomized to receive ketamine (73 ± 26) and fentanyl (69 ± 26; mean difference [95% CI] = 4 [-7 to 15]). The cumulative number of side effects was 2.2 times higher in the ketamine group, but there were no serious adverse events and no patients in either group required intervention. The most common side effects of ketamine were bad taste in the mouth (37; 90.2%), dizziness (30; 73.2%), and sleepiness (19; 46.3%). The most common side effects of fentanyl were sleepiness (15; 36.6%), bad taste in the mouth (9; 22%), and itchy nose (9; 22%). No patients experienced respiratory side effects. At 20 minutes, the mean pain scale score reduction was 44 ± 36 for ketamine and 35 ± 29 for fentanyl (mean difference = 9 [95% CI = -4 to 23]). Procedural sedation with ketamine occurred in 28 ketamine patients (65%) and 25 fentanyl patients (57%) prior to completing the study.
CONCLUSIONS: Intranasal ketamine was associated with more minor side effects than intranasal fentanyl. Pain relief at 20 minutes was similar between groups. Our data support the feasibility of a larger, noninferiority trial to more rigorously evaluate the safety, efficacy, and potential opioid-sparing benefits of intranasal ketamine analgesia for children with acute pain.
参考来源
- Reynolds SL, Bryant KK, Studnek JR, et al. Randomized Controlled Feasibility Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children with Suspected Extremity Fractures. Acad Emerg Med. 2017. PMID: 28926159. doi:10.1111/acem.13313
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。